City of Hope receives $2.3 million R01 grant from NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CITY OF HOPE received a $2.3 million R01 research project grant from NCI to fund studies associated with a phase I/II clinical trial in relapsed/refractory adult acute myeloid leukemia. The research team will be led by Steven Rosen, City of Hope’s provost and chief scientific officer.

The phase II clinical trial will test 8-chloro-adenosine in AML patients whose disease has failed to respond to initial chemotherapy. The research will also detail the drug’s mechanism of action, and further characterize the cytotoxic effect of the drug on leukemia stem cells. In addition, researchers will conduct genomic profiling of AML cells to generate gene expression signatures that may help identify patients who may particularly benefit from 8-chloro-adenosine treatment.

The Rising Tide Foundation will fund the clinical trial testing the drug’s safety and efficacy, while the NCI grant will fund correlative studies in genomic profiling and the drug’s mechanism of action in patients.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login